PXL770 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 20 | 副腎白質ジストロフィー | 2 |
20. 副腎白質ジストロフィー
臨床試験数 : 61 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05146284 (ClinicalTrials.gov) | December 2022 | 16/11/2021 | Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | A Randomized Open-label Phase 2a Study to Assess PXL770 After 12 Weeks of Treatment in Male Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | Adrenomyeloneuropathy | Drug: PXL770 | Poxel SA | NULL | Not yet recruiting | 18 Years | 65 Years | Male | 24 | Phase 2 | NULL |
| 2 | EUCTR2021-006223-18-DE (EUCTR) | 03/05/2022 | 17/01/2022 | Trial on patients with adrenomyeloneuropathy to assess PXL770's behaviour, a new potential medicine, in the body | A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN) - START770 | Adrenomyeloneuropathy (AMN);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: PXL770 Product Code: PXL770 Other descriptive name: PXL770 | Poxel S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 24 | Phase 2 | Germany |